The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma
In this interview, Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, presents the initial data from a Phase Ib study (NCT02513186) investigating isatuximab, an anti-CD38 monoclonal antibody, plus bortezomib-lenalidomide-dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Ocio reveals that isatuximab plus VRd, followed by isatuximab plus Rd, is well tolerated, with few toxicities and high response rates.
